lutetium has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backer, JM; Backer, MV; Blankenberg, FG; Goris, MG; Hamby, CV; Levashova, Z | 1 |
| Ercaliskan, A; Eskazan, AE; Kabasakal, L; Kucukyurt, S; Yagiz Ozogul, Y | 1 |
2 other study(ies) available for lutetium and su 11248
| Article | Year |
|---|---|
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Humans; Indoles; Lutetium; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Radioisotopes; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.
Topics: Bone Marrow; Chemoradiotherapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radioisotopes; Sunitinib | 2020 |